发明名称 Cancer-related extracellular matrix signatures and related methods and products
摘要 Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
申请公布号 US9526800(B2) 申请公布日期 2016.12.27
申请号 US201314389080 申请日期 2013.03.14
申请人 Massachusetts Institute of Technology;The General Hospital Corporation;The Broad Institute, Inc. 发明人 Hynes Richard O.;Naba Alexandra;Clauser Karl;Carr Steven A.;Tanabe Kenneth
分类号 A61K47/48;A61K38/48;C07K16/00;G01N33/574;A61K31/138;A61K31/192;A61K31/197;A61K31/215;A61K31/727;C07K16/40;C12N15/113 主分类号 A61K47/48
代理机构 Wolf, Greenfield & Sacks, P.C. 代理人 Wolf, Greenfield & Sacks, P.C.
主权项 1. A method of delivering an active agent to a tumor for treating or developing treatments, comprising administering to a colon cancer subject having a tumor binding reagents each of which interact specifically with an extracellular matrix (ECM) protein of a set of proteins characteristic of an ECM protein signature, wherein the binding reagents are conjugated to active agents in an effective amount to deliver the active agents to the tumor, wherein the signature ECM proteins includes at least 3 of the proteins selected from an ECM protein signature defined as being characteristic of metastatic primary colon carcinoma (group 4) but not including MMP9, MMP2, SPARC and/or TGFβ1, colon carcinoma metastases (group 5) but not including SPP1, metastatic colon carcinoma (primary & secondary) (group 6) but not including CTSB and/or S100A8, or a signature whose expression is associated with colon cancer or metastatic colon cancer (group 7) but not including MMP9, MMP2, SPARC, TGFβ1, SPPI, LOXL2, CTSB and/or S100A8.
地址 Cambridge MA US